Study M918
Study name | Zhang KK 2022 |
Title | Methamphetamine disturbs gut homeostasis and reshapes serum metabolome, inducing neurotoxicity and abnormal behaviors in mice |
Overall design | The aim of this study was to investigate the impacts of methamphetamine on gut homeostasis and neurotoxicity, and profile the potential metabolic pathways involved. C57BL/6 mice were divided into the following 2 groups: (1) control group, and (2) methamphetamine group. Mice were continuously administered with intraperitoneal saline or methamphetamine (2 mg/kg, 24-h intervals) injections for 5days (day 3-7, the development phase). After the transfer phase (day 8-9, free-injection interval), mice were administered with the same dose of saline or methamphetamine used in the development phase on day 10 (the expression phase). Higher depression levels were observed in mice after methamphetamine treatment. LC/MS analysis was conducted to profile serum metabolites (n = 6/per group). |
Study Type | Type1; |
Data available | Unavailable |
Organism | Mouse; C57BL/6 mouse; |
Categories of depression | Animal model; Other animal model; Other animal model; |
Criteria for depression | Forced swimming test, tail suspension test |
Sample size | 12 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; LC-MS: ExionLCTMAD system (AB Sciex, United States) with Termo UHPLC-Q Exactive Mass Spectrometer; |
PMID | |
DOI | |
Citation | Zhang KK, Chen LJ, Li JH, et al. Methamphetamine disturbs gut homeostasis and reshapes serum metabolome, inducing neurotoxicity and abnormal behaviors in mice. Front Microbiol. 2022 Apr 18;13:755189. |
Metabolite | L-Isoleucine; Hippuric acid; Serotonin; Creatine; L-Acetylcarnitine; LysoPC(18:3(6Z,9Z,12Z)); LysoPE(20:4(5Z,8Z,11Z,14Z)/0:0); LysoPC(20:3/0:0); LysoPE(0:0/20:5(5Z,8Z,11Z,14Z,17Z)); 2-Methylhippuric acid; LacCer(d18:1/12:0); LysoPC(20:1(11Z)); PC(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)); LysoPC(22:4(7Z,10Z,13Z,16Z)/0:0); LysoPE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0); SM(d18:1/22:1(13Z)); LysoPC(22:5(7Z,10Z,13Z,16Z,19Z)/0:0); SM(d18:0/22:1(13Z)); LysoPE(18:2(9Z,12Z)/0:0); 2,2,6,6-Tetramethyl-4-piperidinone; 5,9,11-trihydroxyprosta-6E,14Z-dien-1-oate; Cynaratriol; Loteprednol; 3-hydroxyhexadecanoyl carnitine; Tridecanol; 1-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-glycero-3-phosphate; LysoPA(18:2(9Z,12Z)/0:0); PE(18:0/18:3(9Z,12Z,15Z)); PI(20:0/16:0); Methylisopelletierine; 2-Dodecylbenzenesulfonic acid; Araliacerebroside; 10-Hydroxy-8-nor-2-fenchanone glucoside; 3alpha,7alpha,12beta-Trihydroxy-5beta-cholanoic acid; 3b,12a-Dihydroxy-5a-cholanoic acid; 6-Butyltetrahydro-2H-pyran-2-one; |
